Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina by Bell, Oliver H et al.
                          Bell, O. H., Carreño, E., Williams, E. L., Wu, J., Copland, D. A., Bora,
M., Kobayter, L., Fruttiger, M., Sim, D. A., Lee, R. W. J., Dick, A. D., &
Chu, C. J. (2020). Intravenous indocyanine green dye is insufficient
for robust immune cell labelling in the human retina. PLoS ONE,
15(2). https://doi.org/10.1371/journal.pone.0226311
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1371/journal.pone.0226311
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/abs/pii/S0360319920302779 . Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/
RESEARCH ARTICLE
Intravenous indocyanine green dye is
insufficient for robust immune cell labelling in
the human retina
Oliver H. BellID1, Ester Carreño2, Emily L. Williams1, Jiahui Wu1, David A. Copland1,
Monalisa Bora2, Lina Kobayter2, Marcus Fruttiger3,4, Dawn A. Sim4, Richard W.
J. Lee1,2,3,4, Andrew D. Dick1,2,3,4, Colin J. Chu1,2*
1 Academic Unit of Ophthalmology, Department of Translational Health Sciences, Faculty of Health
Sciences, University of Bristol, Bristol, United Kingdom, 2 Bristol Eye Hospital, University Hospitals Bristol
NHS Foundation Trust, Bristol, United Kingdom, 3 UCL Institute of Ophthalmology, London, United Kingdom,
4 Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
* colin.chu@bristol.ac.uk
Abstract
It is not currently possible to reliably visualise and track immune cells in the human central
nervous system or eye. Previous work demonstrated that indocyanine green (ICG) dye
could label immune cells and be imaged after a delay during disease in the mouse retina.
We report a pilot study investigating if ICG can similarly label immune cells within the human
retina. Twelve adult participants receiving ICG angiography as part of routine standard of
care were recruited. Baseline retinal images were obtained prior to ICG administration then
repeated over a period ranging from 2 hours to 9 days. Matched peripheral blood samples
were obtained to examine systemic immune cell labelling and activation from ICG by flow
cytometry with human macrophage cultures as positive controls. Differences between the
delayed near infrared ICG imaging and 488 nm autofluorescence was observed across
pathologies, likely arising from the retinal pigment epithelium (RPE). Only one subject dem-
onstrated ICG signal on peripheral blood myeloid cells and only three distinct cell-sized sig-
nals appeared over time within the retina of three participants. No significant increase in
immune cell activation markers were detected after ICG administration. ICG accumulated in
the endosomes of macrophage cultures and was detectable above a minimum concentra-
tion, suggesting cell labelling is possible. ICG can label RPE and may be used as an addi-
tional biomarker for RPE health across a range of retinal disorders. Standard clinical doses
of intravenous ICG do not lead to robust immune cell labelling in human blood or retina and
further optimisation in dose and route are required.
Introduction
It is not currently possible to reliably visualise and track immune cells in human central ner-
vous system tissues. The eye is unique as the only fully-accessible and optically-transparent
neural organ in the human body. Indocyanine green (ICG) is a safe and widely-used
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angiographic dye employed in routine ophthalmic practice for the diagnosis and monitoring
of retinal disease [1]. Previously published work identified that ICG administered as a systemic
depot injection in the mouse could label myeloid immune cells in the inflamed retina after 48
hours which could be imaged using commercially-available platforms [2]. This approach
could advance our understanding of ocular disease and responses to treatment if similar find-
ings can be demonstrated in man.
Equally, it has been shown in patients with rheumatoid arthritis and psoriatic arthritis that
joints with active arthritis selectively accumulate more ICG than joints from healthy patients,
when measured in the hands of patients and controls [3]. Furthermore, ICG colocalised with
macrophages in the lipid-rich atheromas within 20 minutes of intravenous injection in an
experimental model in rabbits [4]. This suggests that ICG could selectively accumulate within
macrophages and granulocytes.
Following intravenous ICG administration, the main peak of absorption is at a wavelength
of 805 nm and the peak of fluorescence emission ranges from 820 to 835 nm, within the near
infrared spectrum [5]. It is however well-recognised that the ICG absorption spectra and to a
lesser extent the emission spectra, can shift depending on concentration and the other constit-
uents in solution [6]. ICG is injected as an intravenous bolus for ocular angiography up to a
maximum of 25 mg in usual practice and retinal images are typically only captured over the
first 30-minutes. This means that labelling of cells may not have been observed previously in
the human eye, as it is unlikely that cells will have had enough time to be labelled with ICG or
to infiltrate the eye if stained peripherally.
ICG is known to enhance the visibility of the retinal pigment epithelium (RPE) mosaic and
has been used in adaptive optics imaging [7, 8]. This staining has also been seen late after
administration in the normal rat retina [9] in an approach termed delayed near-infra red anal-
ysis (DNIRA). It has been suggested this may provide a marker of RPE status in addition to
488 nm autofluorescence but has not been extensively investigated in a clinical setting. With
diffuse background staining of RPE by ICG, any signal from immune cell ICG labelling would
need to exceed the RPE signal intensity to be detected. This was achieved during retinal
inflammation after depot ICG administration in the mouse [2].
Here we report a pilot human study that begins the translation of findings from rodent sys-
tems starting by determining if ICG could permit the imaging of immune cells within the
human retina using standard intravenous ocular angiographic doses. By extending the imaging
period and analysing matched peripheral blood samples we aimed to determine if the currently
employed doses and route are sufficient for wider application.
Materials and methods
Ethics
The study was prospectively registered with the ISRCTN registry under study number
30128134 (https://doi.org/10.1186/ISRCTN30128134). Ethical approval was obtained from the
United Kingdom Health Research Authority and local NHS Research Ethics Committee (17/
SW/0030). Human blood samples were handled in accordance with the Human Tissue Act
2004 and the research followed the tenets of the Declaration of Helsinki. Written informed
consent was obtained from all participants.
Recruitment criteria
Twelve adult participants (�18 years) receiving ICG angiography as part of routine standard
of care were recruited. Participants required a suspected diagnosis of neovascular age-related
macular degeneration (nAMD), central serous retinopathy (CSR) or intermediate, posterior
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and panuveitis. The rationale for combining these diverse patient groups was based on the
hypothesis that myeloid immune cells will be present and intraocular leakage of fluid might
accumulate ICG at a sufficient concentration within the retina itself.
Ocular inclusion criteria for nAMD or CSR were: 1) likely or suspected choroidal neovascu-
lar membrane or central serous retinopathy that clinically required ICG angiography (with or
without combined fluorescein angiography); 2) macular sub-retinal fluid present and at least
500 μm in diameter on spectral-domain (SD) optical coherence tomography (OCT) scan; 3)
any obscuring haemorrhage should not exceed more than 50% of the area of the sub-retinal
fluid; 4) not due for intravitreal injection or photodynamic therapy within the first 48 hours of
the study period.
Ocular inclusion criteria for uveitis included: 1) likely or suspected intermediate or poste-
rior uveitis or panuveitis that clinically requires ICG angiography (with or without combined
fluorescein angiography); 2) clinically-suspected vasculitis; 3) no intravitreal therapy adminis-
tered within 3 months prior or will be administered during the study period; 4) mild vitritis
only (with a SUN haze score�2) to not obscure retinal imaging [10].
The following general exclusion criteria applied: 1) known fluorescein, ICG, iodine, or
shellfish allergy; 2) any known contraindication to topical tropicamide and phenylephrine
dilating drops; 3) known renal (eGFR�80 mL/min/1.73 m2) or hepatic dysfunction or active
diseases that in the opinion of the investigator will contraindicate the administration of ICG;
4) inability to be easily imaged on the Spectralis, Optos or Topcon retinal imaging machines
(e.g. marked kyphosis or physical impairment); 5) significant media opacity leading to poor
image quality (e.g. vitreous haemorrhage or cataract); 6) inability to donate a peripheral blood
sample or known HIV, Hepatitis B/C; 7) pregnant or lactating women; 8) unable to consent to
study participation or 9) already enrolled in another research trial.
As a pilot study, an exact sample size was not calculated in advance. Participant blood sam-
ples were anonymised, and laboratory staff and imaging technicians were masked to clinical
details. Image analysis was performed by CJC and EC with full clinical details available.
Study visits and interventions
Following consent, participants underwent collection of clinical and medication history, fol-
lowed by ocular and systemic examination with recording of weight, blood pressure, pulse,
and temperature. Retinal imaging by colour photography, SD-OCT, infrared reflectance, and
488 nm and 780 nm (standard) and 532 nm and 802 nm fundus autofluorescence (ultra-wide-
field) was performed at baseline, prior to ICG and fluorescein angiography (where indicated as
part of standard of care). The same imaging set was performed after 2, 4, 6, and 8 hours post-
ICG injection. Follow-up imaging was performed at a minimum of a further two timepoints of
either 24 hours, 48 hours, 7 days, and 9 days post-ICG injection (S1 Table). Each subject
received a single injection of ICG at baseline only. No adverse events occurred during the
study.
A peripheral blood sample of up to 10 mL was taken from the contralateral arm of that
injected with ICG at either 2 or 4 hours post-administration and at a later, broad range of
timepoints (24 or 48 hours, or 7 days post-administration) to maximise the chance of detecting
a positive signal, given the expected time to labelling was unknown. Where possible following
a study amendment, a pre-injection blood sample from the same participant was also obtained
for the first flow cytometric run for direct comparison pre- and post-administration–for more
robust ICG gating but to also assess potential changes in activation markers of the immune
cells to a patient’s own baseline. For the second run (days later) fresh healthy donor blood was
used as a control, rather than storage and reuse of the participant’s own blood, due to potential
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depletion of subsets of immune cells as ICG-free blood was required to enable preparation of a
fluorescence-minus-one (FMO) control to assists with gating. Blood samples were processed
within 30 minutes of venepuncture for flow cytometry.
Retinal imaging platforms
Retinal angiography and imaging were performed using two different devices: a Spectralis
HRA+OCT system (Heidelberg Engineering, Heidelberg, Germany) and an Optos California
(Optomap, Optos plc, Scotland, UK). Colour fundus photography used a TRC-50DX camera
(Topcon Medical, Tokyo, Japan). SD-OCT imaging was obtained on the Spectralis system.
Cell preparation
Human blood-derived macrophages: (hBDMs). One mM of EDTA and 50 μL/mL
RosetteSep human monocyte enrichment cocktail (STEMCELL Technologies, Vancouver,
Canada) were added to blood and incubated for 20 minutes at room temperature before dilu-
tion with an equal volume of PBS enriched with 2% FCS. Cells were isolated by Ficoll gradient
and resuspended at 0.5�106 cells/mL in RPMI complete media (RPMI supplemented with 10%
FCS, 2 mM L-glutamine, and 100 U/mL penicillin streptomycin). Fifty ng/mL M-CSF was
added and cells were seeded at 2 million CD14+ cells per well of a 6-well plate. Media exchange
was performed on days 4, 7 and 10.
PBMCs. Whole blood was prepared for ficoll as described above, with the exception that
the RosetteSep human monocyte enrichment cocktail was not used. After centrifugation, cells
were re-suspended to 0.5�106 cells/mL in freezing media (15% FCS and 10% v/v DMSO in
RPMI complete media) and frozen at -80˚C. Cells were thawed by adding pre-heated RPMI
complete media prior to use.
ICG (in vitro). ICG (25 mg powder for solution for injection; PL 44791/0001, Diagnostic
Green, Aschheim-Dornach, Germany) was dissolved to a stock solution of 5 mg/mL in pure
water before dilution into cell culture media as required.
Flow cytometry
hBDMs and whole blood. One-hundred μL of samples were added to each well of a V-
well bottomed plate, 100 μL LIVE/DEAD Fixable Violet Dead Cell Stain (L34955; Thermo
Fisher Scientific) was added (to a final dilution of 1:1000 in PBS), and incubated at 4˚C for 15
minutes. Each well was re-suspended with 50 μL of an antibody cocktail and incubated at 4˚C
for 30 minutes; two antibody cocktails were used: 1) FITC-conjugated anti-human CD3 mAb
(Clone UCHT1; BD Biosciences), PE-conjugated anti-human CD4 mAb (Clone RPA-T4; BD
Biosciences), PE-dazzle594-conjugated anti-human CD66b mAb (Clone G10F5; Biolegend,
San Diego, CA), PerCP-Cy5.5-conjugated anti-human CD62L mAb (Clone DREG-56; Biole-
gend), BV605-conjugated anti-human CD25 mAb (Clone BC96; Biolegend), APC-conjugated
anti-human CD69 mAb (Clone FN50; Biolegend); 2) PE-dazzle594-conjugated anti-human
CD66b mAb, eVolve 605-conjugated anti-human CD14 mAb (Clone 61D3; eBioscience
(Thermo Fisher Scientific)), BV711-conjugated anti-human HLA-DR mAb (Clone L243; Bio-
legend), APC-conjugated anti-human CD80 mAb (Clone 2D10; Biolegend) (all antibodies
were diluted in FWB (2% v/v FCS and 1 mM EDTA in PBS); residual volume of blood was
considered to be 20 μL). Two-hundred μL of BD FACS lysing solution (349202) was then
added and incubated at room temperature for 10 minutes, washed and prepared for flow
cytometry acquisition.
For antibody cocktail 1, cells were gated-for on size and granularity (FSC-A vs. SSC-A) and
singlets (FSC-A vs. FSC-H), then live cells (LIVE/DEAD Fixable Violet; gate-drawing was
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assisted by heat-killed cells), then for CD3+CD4+ (CD4+ T cells), CD3+CD4- (CD4- T cells),
and CD3- cells, and (via the CD3- gate) for CD66b+ (granulocytes), and CD4int cells (mono-
cytes). Cell populations were subsequently gated-for on activation markers using FMO con-
trols (CD25 [11], CD62L [12–14], and CD69 [11]; S1 Fig).
For antibody cocktail 2, live cell singlets were gated-for as described above, and then CD14+
CD66b- cells (monocytes) were gated-for (CD14 gate-drawing was assisted by FMO controls).
The monocytes were subsequently gated-for on activation markers using FMO controls
(HLA-DR [15] and CD80 [16]).
For all flow cytometry experiments, 1 μL of mAbs were also added to one drop of compen-
sation beads (Anti-Rat Ig, κ/Negative Control Compensation Particles Set (BD Biosciences))
to prepare single-stain controls for compensation; for live-dead compensation, either heat-
killed cells or the ArC Amine Reactive Compensation Bead Kit (Invitrogen) were used. Sam-
ples were acquired using a BD LSRFortessa X-20 using BD FACSDIVA software (BD
Biosciences).
Light microscopy
Cells were washed 5 times (for 5 minutes each) in PBS. Images were acquired on an EVOS FL
Color Imaging System (Thermo Fisher Scientific).
Data analysis
Flow cytometry data was analysed and presented using FlowJo v10 (FlowJo LLC, Ashland,
OR). Statistical analysis was performed using Prism 7 (GraphPad Software Inc., San Diego,
CA). Participant data (percentage positive cells or MFI) was analysed using the Kruskal-Wallis
test (one-way ANOVA [17]), with FDR step-up correction of p-values [18].
Results
It has been identified that systemic ICG administration in the mouse could label myeloid
immune cells which were then visualised in the retina [2]. To determine if it could be used for
immune cell labelling in man an experimental pilot study was initiated. As ICG is already rou-
tinely used for ocular angiography at accepted doses, twelve adults with an existing ocular indi-
cation for ICG administration (as part of their standard of care) were enrolled and imaged for
up to nine days following angiography. Following a study amendment, from participant 3
onwards the maximum dose of 25mg was always injected. Demographics and the weight-
adjusted dose of ICG administered are summarised in Table 1.
Delayed retinal imaging after ICG administration reveals disparities
between standard autofluorescence
Near-infrared (790 nm excitation) retinal autofluorescence signals were minimally detectable
or absent at baseline in most of the patients, but clearly visible in all following ICG administra-
tion, even nine-days later (S1 Fig). Differences in signal patterns between this DNIRA and
standard 488 nm autofluorescence could be seen across a range of ocular pathology (Fig 1) and
may provide an additional method for visualising RPE and cell health.
ICG labelling of Human immune cells in vivo is not robust using standard
intravenous doses
Only one subject demonstrated ICG signal on peripheral blood immune cells using flow
cytometry. Angiography confirmed an acute choroidal neovascular membrane (CNV) which
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had been symptomatic for five days prior to ICG injection (Fig 2A–2D). Discrete signals
around the CNV lesion were visible only in the near-infrared channel and were approximately
30 μm in diameter compatible with myeloid cells (Fig 2E and 2F). Longitudinal observation
demonstrated alteration in position of these signals between the 24 hour and 7 day imaging
intervals without corresponding changes in 488 nm autofluorescence, indicating the changes
are unlikely to arise from the RPE. It is possible these may represent labelled cells, but the only
characteristic possible to confirm this would be movement in position across time, though the
Table 1. Demographics of participants enrolled in the study with a clinical indication for routine ICG angiography.
ID Age
(years)
Gender
(M/F)
ICG
indication and
eye
Weight
(kg)
Dose
of
ICG�
(mg/
kg)
Lens
Status
Visual
Acuity
RE
(Letter
score)
Visual
Acuity
LE
(Letter
score)
Past Medical History Current systemic
medication
Recent ocular
medication
ICG+ cells
detected
in blood
1 76 M nAMD LE 96 0.08 C 73 62 Treated Bladder and
Prostate Carcinoma
Atorvastatin Aflibercept 2
days prior
NO
2 78 F nAMD BE 58 0.30 IOL 72 78 None Multivitamin
supplements
Lucentis 6
months prior,
previous PDT
NO
3 79 F nAMD RE 112 0.22 C 63 81 Hysterectomy and
stoma from bowel
injury. TIA
Lutein None YES
4 22 F Uveitis BE
(MFC)
125 0.20 N 75 2 None Tacrolimus,
Mycophenolate
mofetil
None NO
5 79 F nAMD RE 75 0.33 C 42 79 None None Aflibercept one
month prior
NO
6 64 F nAMD LE 65 0.38 N 78 34 Depression,
hypertension
Paroxetine None NO
7 76 F Uveitis BE
(Panuveitis)
60 0.42 IOL 83 65 Ocular sarcoidosis None None NO
8 30 M Uveitis BE
(Panuveitis)
84 0.30 IOL 83 85 Arthritis of the knee None Ozurdex one
month prior
& topical
prednisolone
NO
9 86 F nAMD LE 87 0.29 IOL 76 6 Hiatus hernia,
osteoporosis,
hypertension,
hypercholesterolaemia
Lansoprazole,
Adcal D3,
Lisinopril,
Cefalexin
Aflibercept six
months prior
NO
10 78 M CSR BE 72 0.35 N 37 60 Polymyalgia rheumatica,
hypertension, Diabetes
Mellitus, Myeloma
Prednisolone,
Amlodipine,
Atorvastatin,
Metformin,
Cholecalciferol,
Ramipril
None NO
11 34 F Uveitis BE
(Panuveitis)
56 0.45 IOL 79 60 Tuberculosis,
Sarcoidosis
Rifater,
Moxifloxacin,
Pyridoxime
Dexamethasone
& Dorzolamide
drops
NO
12 74 F nAMD LE 90 0.28 N 78 15 None Atorvastatin,
Clopidogrel,
Indapamide MR
None NO
ID = identification number, nAMD = neovascular age-related macular degeneration, CSR = Central serous retinopathy, MFC = Multifocal Choroiditis with Panuveitis,
LE = Left eye, RE = Right eye, BE = Both eyes, N = No cataract, C = cataract, IOL = intraocular lens, TIA = transient ischaemic attack.
�Note total ICG dose injected was increased to a fixed maximal 25mg from participant 3 onwards.
https://doi.org/10.1371/journal.pone.0226311.t001
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speed of change is unknown. There was no evidence of systemic infection or inflammation in
this participant to explain why ICG signal was present in the blood.
Compensating for the potential confounding factor of signal arising from RPE dysfunction
and the expected rare occurrence of labelled immune cells using the intravenous ICG route, it
was possible to identify distinct cell-sized signals (Fig 3) in only three locations of three sub-
jects. In each, the DNIRA signals newly-appear over time in a region where there is no alter-
ation in 488 nm autofluorescence. No ICG signal was observed in the retinal vasculature at late
timepoints, in agreement with published data, showing it has a relatively short half-life of min-
utes in the circulation [19, 20].
No peripheral blood immune cell activation was observed following ICG
administration
For a subset of participant blood samples, it was possible to measure activation markers using
flow cytometry (Fig 4, S2 and S3 Figs). Aggregate data did not demonstrate evidence of ICG
resulting in an inflammatory or activated immunophenotype. As only one subject had detect-
able ICG signal in peripheral blood, in vitro human macrophage cell cultures were used to
examine their ability to develop ICG-positive signals on flow cytometry. Microscopy demon-
strated endosomal accumulation of ICG in both cell cultures at an in vitro dose of 0.2 mg/ml,
implying a sufficient concentration or protracted exposure may be required to achieve label-
ling where cells would be clearly visible if they gain entry into the retina.
Fig 1. Differences in retinal images between late near infrared imaging following ICG (DNIRA) and standard 488 nm autofluorescence. Four examples
from the eyes of different subjects illustrate different appearances that provide complementary information on RPE health. Retinal ICG fluorescence 790 nm
excitation channel images are shown alongside matched 488 nm excitation autofluorescence images. CNV = Choroidal neovascular membrane, CSR = Central
serous retinopathy. LE = left eye, RE = right eye. Scale bars = 600 μm.
https://doi.org/10.1371/journal.pone.0226311.g001
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Discussion
Whilst immune cell labelling was the central objective, we illustrate a range of retinal pathology
can be imaged late after ICG administration, with distinctive signals arising from the RPE.
DNIRA has been described before, but here we demonstrate findings across a further diverse
range of human ocular pathology using a commercially available SLO platform [9] that com-
plements recent findings using adaptive optics imaging of the RPE in inherited retinal degen-
erations [8]. Several examples of unique patterns only seen by DNIRA identify additional or
complementary information for monitoring RPE health versus traditional 488 nm autofluores-
cence imaging. These data highlight an opportunity for superior stratification and earlier
detection of pathology such as reversible RPE dysfunction, critical to identifying therapeutic
response signals, as has remained problematic for example in studies of geographic atrophy
[21].
In terms of immune cell labelling, using the intravenous route with standard angiographic
doses does not achieve robust labelling within the retina. ICG-positive myeloid cells were only
detected in the peripheral blood of subject 3, in which distinct near infrared punctate signals
appeared without corresponding 488 nm signal alterations. These new signals of the appropri-
ate size for a leukocyte changed over time and might represent immune cell trafficking of an
ICG-labelled cell. Two similar signals were only seen in two other eyes of two different partici-
pants. The only feasible non-invasive method of characterising them as immune cells in man
would be to identify clear movement over a period of minutes to hours. Co-labelling with
Fig 2. Only one subject demonstrated ICG-positive cells in peripheral blood and retinal signals that altered over time. (A) Subject 3 presented a week
following new onset visual loss and distortion in the right eye. Existing RPE pigment abnormalities were visible on colour fundus images, (B) with a large
pigment epithelial detachment and subretinal fluid visible on spectral-domain OCT. (C) A choroidal neovascular membrane was confirmed by fluorescein and
ICG angiography, at 90 and 40 seconds post-injection respectively. (D) Optos ultra-widefield ICG imaging (802 nm excitation) confirmed regions of leakage or
high signal were present only at the macula. (E) At different points timed from ICG administration, Spectralis HRA imaging demonstrated punctate signals in
the ICG channel only (790 nm excitation) that altered markedly between 24 hours and day 7. (F) Enlarged region illustrating changes in signal intensity and
location. (G) Flow cytometry histogram of the peripheral blood sample taken at 24 hours demonstrating ICG+ signal (green) on monocyte and granulocyte
populations compared to a no-ICG control (grey). Scale bars = 200 μm unless stated.
https://doi.org/10.1371/journal.pone.0226311.g002
Fig 3. Cell-sized hyperfluorescent near-infrared signals appearing in regions with no prior autofluorescence or RPE signal change during the study.
Retinal ICG fluorescence 790 nm excitation channel images are shown alongside matched 488 nm excitation autofluorescence images. Subject 3 had
detectable ICG cell staining in peripheral blood. By size and location these could represent weakly ICG labelled cells infiltrating the retina, rather than
arising from RPE staining alone. LE = left eye, RE = right eye. Scale bars = 200 μm.
https://doi.org/10.1371/journal.pone.0226311.g003
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cellular dyes or antibodies are not currently established. No rapid alterations were seen during
imaging sessions, potential cell labelling could only be identified in post-processing and the
expected speed of migration within retinal tissue remains unknown. Evidence from 2-photon
imaging of the inflamed mouse eye however demonstrates myeloid cell movement may be
much slower than expected, even compared to other tissues, at around 1 μm per minute [22].
This could explain the larger time intervals required to observe signal position shifts that could
represent labelled immune cells. Complementing our data and drug safety, no evidence of
immune cell activation could be detected in peripheral blood following intravenous ICG
injection.
To better understand the pharmacodynamics of ICG in relation to cellular accumulation,
we tested human-derived macrophage cell cultures which confirmed the localisation of ICG
within extranuclear vesicular structures. Whilst not directly comparable to the in vivo situa-
tion, this suggests if the correct delivery and concentration can be achieved, labelling is possi-
ble. The intracellular localisation is in contrast with other cells such as hepatocytes, where
nuclear localisation has been observed, suggesting differential uptake or processing routes
[23]. The uptake of ICG has been shown, in primary human RPE cultures, to be dependent on
the Na+/K+-ATPase pump and localised within extranuclear compartments [24]. It has also
been observed to bind the RPE of human, primate, and mouse subjects in vivo [9, 25]. In
Fig 4. ICG administration did not activate immune cells in peripheral blood but can be observed in endosomes of macrophage cell cultures. (A)
Aggregated flow cytometry activation marker changes in participant peripheral blood samples taken across the study are shown measuring CD62L on T-cells
(p = 0.914), (B) CD80 on monocytes (p = 0.914), and (C) CD62L on granulocytes (p = 0.698). Each point is a single blood sample from 7 subjects. All activation
markers underwent validation with positive control stimuli. Human macrophage cell cultures developed visible signal within endosomes following 24 hours of
culture with 0.2 mg/mL ICG by microscopy, which could be detected by flow cytometry in the near infrared channel. (D) Representative images shown for
human cell cultures, with (green histogram) and without (grey histogram) ICG administration. Scale bars = 10 μm.
https://doi.org/10.1371/journal.pone.0226311.g004
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Subject 3, several cell types were weakly-positive for ICG and this is likely due to membrane
binding as ICG is well-characterised as able to bind to amphiphilic structures [26]; however
the phagocytic populations (monocytes and granulocytes) were far more strongly-positive for
ICG than other immune cells. This suggests that ICG may be internalised and accumulated by
these cells, comparable to that observed in our macrophage cell cultures and may therefore be
the only visible population brighter than the RPE if they enter the retina.
Our findings highlight the potential of ICG, though considerably more refinement is
needed prior to further clinical application because we identified ICG-positive blood in only
one subject at 24 hours post-administration. It was not possible to test peripheral blood at
every imaging visit, so positive findings may have been missed. Preclinical mouse data sug-
gested the intravenous route of ICG administration would not provide the most efficient cell
labelling, but it was prudent from an ethical and practical perspective to show the established
administration route was insufficient [2]. The results of this study provide justification to pur-
sue alternative methods of administration, reformulation or higher doses.
In clinical hepatic function studies, approximately ten-fold higher systemic ICG doses than
used here have been given successfully without clear evidence of toxicity [27]. This dose has
typically only been given as a bolus and given the endosomal accumulation and preferential
staining of myeloid cells with phagocytic potential, it is likely more sustained exposure of cells
to a minimal concentration of ICG would be needed for efficient labelling. The superior intra-
peritoneal or subcutaneous routes identified in mouse are not readily applicable in man given
the safety, dose, and side-effect considerations for ocular application [2]. However, administra-
tion by slow intravenous infusion or reformulation to an oral preparation may be preferable
and our in vitro modelling suggests a sustained blood level of even 6 μg/ml of ICG for two
hours might enable strong cell marking to be reliably detectable using flow cytometry (S2 Fig).
With improvement in the efficiency of cell labelling, the relative amplitude of signal from
immune cells against that of the RPE could result in clear separation of the two, as achieved in
the mouse [2]. Furthermore, engaging methods of superior imaging resolution such as adap-
tive optics scanning laser ophthalmoscopy will allow single immune cells to be clearly distin-
guished from the RPE, identified and tracked. This study provides further support towards the
translational goal of imaging the cellular components of the immune system in the human eye
and with considerable refinement ICG might be a viable method to achieve this.
Supporting information
S1 Table. Imaging session and blood sample collection timings for each participant. Mea-
sured from time of ICG injection. Timings were determined by participant availability and fol-
lowing an amendment, extension to cover a range of longer intervals to maximise the chance
of signal detection.
(DOCX)
S1 Fig. Baseline 488 and 790 nm fundal images. A representative selection of baseline images
acquired from patients in the study illustrating weak to minimal infrared autofluorescence
prior to ICG administration. Scale bars = 300 μm.
(TIF)
S2 Fig. Representative gating strategy used to analyse human blood. (A) The representative
gating strategy used for antibody cocktail #1 (“lymphocyte panel”) is shown. For antibody
cocktail #2 (“monocyte panel”), live cells were gated into granulocytes (CD66b+) or monocytes
(CD14+ CD66b-, a CD14 FMO was used to assist with drawing the CD14+ gate)). For the histo-
grams (activation markers: CD25, CD62L, and CD69), FMOs are indicated in red, whilst a
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representative participant sample is indicated in blue. Validation of the activation marker anti-
bodies was performed via whole-blood staining (individually for 24 hours) with phytohaemag-
glutin P (PHA; at a final concentration of 20 μg/mL), CD3/CD28 activating beads (Dynabeads;
0.63 μL of beads (stock concentration 4.0 � 107 beads/mL) were used), and li popolysaccharide
(LPS; at a final concentration of 0.1 ng/mL). (B) Representative histograms from an experi-
ment where whole human blood was stained ex vivo with 6 ug/mL indocyanine green (ICG)
for 2 hours (green), as compared to an ICG FMO sample (grey). The staining is less bright
than has been observed with cell lines and the participant data, possibly due to the abundance
of erythrocytes (as compared-to cell cultures), lower ICG concentration, and/or shorter stain-
ing time.
(TIF)
S3 Fig. Scatterplots showing changes in activation after ICG administration. (A–B) Scatter-
plots for CD3+CD4+ cells show changes in CD25 and CD69, (C–E) for CD3+CD4- cells show
changes in CD25, CD62L, and CD69, and (F) for CD14+ cells (monocytes) show changes in
HLA-DR. The y-axis is expressed as fold-change in the percentage of positive cells (CD25,
CD62L, CD69) or the fold-change of the MFI (CD80, HLA-DR). Loss of CD62L is associated
with activation, whilst expression of CD25 and CD69, and up-regulation of CD80 and
HLA-DR associate with activation; statistical tests were not significant (p�0.05). The data was
acquired using flow cytometry (n = 7).
(TIF)
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